FDA approval comes early for Regeneron's Eylea in DME
This article was originally published in Scrip
Executive Summary
US FDA approval was granted three weeks early for the Regeneron Pharmaceuticals vascular endothelial growth factor (VEGF) inhibitor Eylea (aflibercept) in the treatment of diabetic macular edema (DME), broadening the blockbuster biologic's label beyond its first two indications.